TG Therapeutics (NASDAQ:TGTX) Posts Earnings Results, Beats Expectations By $0.08 EPS

TG Therapeutics (NASDAQ:TGTX) announced its earnings results on Tuesday. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.08, Briefing.com reports. The business had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The business’s quarterly revenue was up 357.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.34) earnings per share.

TG Therapeutics Price Performance

TGTX stock traded down $0.23 during trading on Wednesday, reaching $20.35. 3,159,167 shares of the company were exchanged, compared to its average volume of 3,662,799. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.84 and a current ratio of 3.62. The stock’s 50 day moving average price is $18.54 and its 200 day moving average price is $16.57. TG Therapeutics has a 52-week low of $6.46 and a 52-week high of $23.12. The company has a market cap of $3.14 billion, a P/E ratio of 91.04 and a beta of 2.23.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TGTX shares. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday. LADENBURG THALM/SH SH upped their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. Finally, HC Wainwright reissued a “buy” rating and set a $49.00 price target on shares of TG Therapeutics in a report on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $31.83.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.